What is the role of CDK inhibitors in cancer therapy?
CDK inhibitors are a class of drugs designed to target and inhibit the activity of CDKs. By blocking the function of specific CDKs, these inhibitors can halt the proliferation of cancer cells. For example, CDK4/6 inhibitors such as palbociclib, ribociclib, and abemaciclib have shown significant efficacy in treating hormone receptor-positive breast cancer. These inhibitors help to restore cell cycle control and induce cell cycle arrest, thereby reducing tumor growth.
